抑制MTA1对雌二醇调控ER阳性乳腺癌细胞MMP-9、TIMP-1表达的影响

doi:10.11904/j.issn.1002-3070.2014.06.005

Abstract

Abstract:

Objective To investigate the role of metastasis associated protein 1(MTA1)in estrogen regulated expression of matrix metalloproteinase-9(MMP-9)and tissue inhibitor of metalprotease-1(TIMP-1)in estrogen receptor (ER)positive breast cancer cells.Methods MTA1 knockdown cell model was generated based on MCF-7 breast cancer cell line by transfected with MTA1-shRNA.The mRNA and protein level of MMP-9 and TIMP-1 in wild type MCF-7(MCF-7^WT)and MCF-7^MTA1-shRNA before and after 17β-estradiol(E₂)treatment were examined by Real-time PCR and Western blot respectively.Results The MTA1-shRNA showed maximally 84.9% suppression of MTA1 expression in MCF-7,suggesting a satisfied MTA1 knockdown cell model was established for subsequent experiments.After treated with E₂ for 48h,MCF-7^WT showed an increment of 46%(P＜0.05)and 37%(P＜0.05)of the mRNA and protein level of MMP-9 and a decrement of 32.3%(P＜0.05)and 18.2%(P＜0.05)of TIMP-1;MCF-7^MTA1-shRNA showed a decrement of 32.3%(P＜0.05)and 18.2%(P＜0.05)of mRNA and protein expression of MMP-9 respectively but no significant difference in TIMP-1 comparing with MCF-7^WT before treated with Estradiol.After E₂ treatment,MCF-7^MTA1-shRNA didn′t show significant change of MMP-9 except decrements of 32.3%(P＜0.05)and 18.2%(P＜0.05)in the mRNA and protein levels of TIMP-1.Conclusion MTA1 may be involved in the pathway by which estrogen regulated the expression of MMP-9 but not TIMP-1 in ER positive breast cancer cells.

Key words: Breast cancer, Estrogen, Metastasis-associated protein 1, Matrix metalloproteinase-9, Tissue inhibitor of metalloproteinases-1

CLC Number:

R73-3

WANG Jing,YU Hang,WANG Peng,XIE Changying,NI Xiuqin. Study on the role of MAT1 in estradiol regulated MMP-9,TIMP-1 expression in ER positive breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 503-507.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2014.06.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2014/V28/I6/503

References

1 Ziegler RG,Anderson WF,Gail MH.Increasing breast cancer incidence in China:the numbers add up[J].J Natl Cancer Inst,2008,100(19):1339-1341.
2 Somiari SB,Somiari RI,Heckman CM,et al.Circulating MMP2 and MMP9 in breast cancer-potential role in classification of patients into low risk,high risk,benign disease and breast cancer categories[J].Int J Cancer,2006,119(6):1403-1411.
3 Kousidou O,Berdiaki A,Kletsas D,et al.Estradiol-estrogen receptor:a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells[J].Mol Oncol,2008,2(3):223-232.
4 Toh Y,Nicolson GL.The role of the MTA family and their encoded proteins in human cancers:molecular functions and clinical implications[J].Clin Exp Metastasis,2009,26(3):215-227.
5 Hamatsu T,Rikimaru T,Yamashita Y,et al.The role of MTA1 gene expression in human hepatocellular carcinoma[J].Oncol Rep,2003,10(3):599-604.
6 Hofer MD,Kuefer R,Varambally S,et al.The role of metastasis-associated protein 1 in prostate cancer progression[J].Cancer Res,2004,64(3):825-829.
7 Toh Y,Oki E,Oda S,et al.Overexpression of the MTA1 gene in gastrointestinal carcinomas:correlation with invasion and metastasis[J].Int J Cancer,1997,74(4):459-463.
8 张华,张明月,王洲,等.肿瘤转移相关基因表达与Ⅰ期非小细胞肺癌预后的相关性[J].肿瘤,2010,30(10):881-885.
9 Li DQ,Pakala SB,Nair SS,et al.Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer[J].Cancer Res,2012,72(2):387-394.
10 马金生,马二民,秦璐莹,等.乳癌组织中MTA1、MMP-9和TIMP-1蛋白的表达[J].郑州大学学报(医学版),2009,44(4):819-821.
11 饶玉梅,王鸿雁,范良生,等.MTA1通过βcatenin、MMP9调节HeLa细胞粘附、侵袭、转移[J].华中科技大学学报(医学版),2011;40(1):32-34.
12 王宏健,尚丹丹,朱筑霞,等.氟维司群对雌激素诱导的MCF-7乳腺癌细胞侵袭及基质金属蛋白酶表达的影响[J].贵阳医学院学报,2014,39(5):633-637.
13 Boonyaratanakornkit V.Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor[J].Steroids,2011,76(9):877-884.
14 Yan D,Avtanski D,Saxena NK,et al.Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3-and MTA1/Wnt1 protein-dependent pathways[J].J Biol Chem,2012,287(11):8598-8612.

[1]	LI Xudong, LIU Tong. The single cell transcriptome sequencing reveals the role and prognostic value of PCLAF and ERO1A in the progression of breast cancer [J]. Journal of Practical Oncology, 2025, 39(5): 418-427.
[2]	MA Dongqiong, YANG Cangjiang, ZHU Yunfang, WEN Hongmei, CAO Jidong, DAI Tangyan, LEI Guoyan, LI Dongke, SHI Qingping. Incidence and mortality of female breast cancer in cancer registration areas of Yunnan Province in 2020 and trend analysis from 2012 to 2020 [J]. Journal of Practical Oncology, 2025, 39(4): 272-277.
[3]	LUO Danli, LI Fucheng, JIA Siyuan, DOU He, BA Yuling, GAO Tian, LI Zhaoting, XIAO Min. Effect of plasma atherosclerosis index on pathological complete response and prognosis of breast cancer patients treated with neoadjuvant chemotherapy [J]. Journal of Practical Oncology, 2025, 39(4): 316-323.
[4]	ZHAO Entong, GUAN Xin, LI Hongyan, QIU Yunting, ZHANG Bingqiang, CHEN Mengmeng, ZOU Wei, QU Chao. SNG162 activates the estrogen signaling pathway at the membrane initiation of glioblastoma by upregulating ER-α36 expression [J]. Journal of Practical Oncology, 2025, 39(3): 177-183.
[5]	WU Dan, WANG Yihai. Current status of radiotherapy resistance research in breast cancer [J]. Journal of Practical Oncology, 2025, 39(3): 262-266.
[6]	WANG Rui, MA Deyuan, JIA Wangqiang, GUAN Quanlin. Application and progress of nano-medicine mediated cuproptosis in the breast cancer treatment [J]. Journal of Practical Oncology, 2025, 39(2): 144-150.
[7]	WANG Shuai, LI Qiqing, LI Rui, XU Tiefeng. Advances in the application of nanoparticles in the diagnosis and treatment of breast cancer [J]. Journal of Practical Oncology, 2025, 39(2): 151-156.
[8]	WANG Ru, ZHANG Hongxia. Research progress on the application of magnetic resonance imaging technology in predicting lymphatic vascular invasion in breast cancer [J]. Journal of Practical Oncology, 2025, 39(2): 162-168.
[9]	GU Wen, ZHOU Lan, JIA Yanni, HUANG Weidong. Validation of measurement attributes for QLU-C10D scale in breast cancer patients [J]. Journal of Practical Oncology, 2025, 39(1): 49-55.
[10]	SHI Changyong, ZHOU Zizhen, ZHOU Guanglin, XIONG Yimin. The values of DCE-MRI quantitative parameters combined with NCAPH in the diagnosis of early breast cancer [J]. Journal of Practical Oncology, 2025, 39(1): 56-60.
[11]	ZHANG Yuqing, JING Jing, LIU Zhaoliang, AN Jing, AN Weiwei. The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer [J]. Journal of Practical Oncology, 2024, 38(5): 313-322.
[12]	YANG Minye, XIAN Tongcheng, LIU Jingjian, BIE Jun, WANG Jie, LUO Yi. The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics [J]. Journal of Practical Oncology, 2024, 38(5): 323-329.
[13]	LIU Dong, ZHANG Taijuan, DANG Jifeng. The research progress of inflammatory reaction driving breast cancer metastasis [J]. Journal of Practical Oncology, 2024, 38(5): 336-341.
[14]	LI Qianni, XU Lingyan, LI Jian, YAO Xuepei, LIU Meina. Trend analysis of a longitudinal evaluation for multidimensional treatment quality of breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 213-220.
[15]	GAO Guangqiang, WANG Falin, LI Juan, TIAN Hong, GUO Sijia, YU Xiaolan, YANG Tingting, LIU Jiaren. β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway [J]. Journal of Practical Oncology, 2024, 38(4): 254-261.

Study on the role of MAT1 in estradiol regulated MMP-9,TIMP-1 expression in ER positive breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments